SAN
RAFAEL, Calif., April 10,
2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive
Officer of BioMarin, will host a conference call and webcast on
Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024
financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: 888-330-3556
International Dial-in Number: 646-960-0826
Conference Call ID: 1816377
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1816377
Interested parties may access a live audio webcast of the
conference call via the investor section of the BioMarin
website, https://investors.biomarin.com/. A replay of the call
will be archived on the site for one week following the call.
About BioMarin
Founded in 1997, BioMarin is a global
biotechnology Company dedicated to transforming lives through
genetic discovery. The Company develops and commercializes targeted
therapies that address the root cause of the genetic conditions.
BioMarin's unparalleled research and development capabilities have
resulted in eight transformational commercial therapies for
patients with rare genetic disorders. The Company's distinctive
approach to drug discovery has produced a diverse pipeline of
commercial, clinical, and pre-clinical candidates that address a
significant unmet medical need, have well-understood biology, and
provide an opportunity to be first-to-market or offer a substantial
benefit over existing treatment options. For additional
information, please visit www.biomarin.com.
Contacts:
|
Investors
|
Media
|
Traci
McCarty
|
Marni Kottle
|
BioMarin Pharmaceutical
Inc.
|
BioMarin Pharmaceutical
Inc.
|
(415) 455-7558
|
(650)
374-2803
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2024-financial-results-conference-call-and-webcast-on-wednesday-april-24-2024-at-430pm-et-302109127.html
SOURCE BioMarin Pharmaceutical Inc.